S-1/A: Theriva Biologics Announces Proposed Public Offering of Common Stock and Warrants

Theriva Biologics is offering up to 2,173,913 shares of common stock, along with common warrants and pre-funded warrants, in a best efforts offering to raise capital for working capital and general corporate purposes.

Summary

• Theriva Biologics, Inc. has filed an amendment to its registration statement for a proposed public offering.
• The offering includes up to 2,173,913 shares of common stock and accompanying common warrants, or pre-funded warrants in lieu of common stock, with each share or pre-funded warrant sold together with a common warrant.
• The assumed public offering price is $3.22 per share of common stock and accompanying common warrant, based on the closing price on September 5, 2024.
• The common warrants will have an exercise price to be determined and will expire five years from the issuance date.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership thresholds of 4.99% or 9.99%, with an exercise price of $0.001 per share.
• A.G.P./Alliance Global Partners is acting as the sole placement agent on a best efforts basis.
• The offering is expected to terminate on October 15, 2024, unless closed earlier or terminated by the company.
• The company intends to use the net proceeds for working capital and general corporate purposes, including research and development and manufacturing scale-up.
• Directors and officers have agreed to a 90-day lock-up period on their shares of common stock.
• The company's common stock is listed on the NYSE American under the symbol TOVX.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting the facts of the offering. The risks are clearly outlined, but the potential benefits of the capital raise are also mentioned. The sentiment is slightly positive as the company is actively seeking funding to advance its pipeline.

Positives

• The offering aims to provide additional working capital for research and development and manufacturing scale-up.
• The inclusion of pre-funded warrants offers flexibility for certain investors.
• The company's stock is already listed on the NYSE American, providing existing liquidity.

Negatives

• The offering is on a 'best efforts' basis, meaning there is no guarantee that all securities will be sold.
• The actual public offering price may be at a discount to the current market price.
• There is no established public trading market for the common warrants and pre-funded warrants.
• The company has broad discretion in the use of the net proceeds from the offering.
• Investors may not receive a refund if the company does not sell enough securities to pursue its business goals.

Risks

• The company may not effectively use the net proceeds from the offering.
• The offering amount is not guaranteed and may be substantially less than the maximum amount set forth in the prospectus.
• The price of the common stock could fluctuate significantly, leading to potential losses for investors.
• There is no public market for the common warrants or pre-funded warrants, limiting liquidity.
• The company does not intend to pay dividends on the common stock in the foreseeable future.
• Provisions of the common warrants and pre-funded warrants could discourage an acquisition of the company by a third party.
• The company may not receive any additional funds upon the exercise of the common warrants or pre-funded warrants.
• Stockholders may experience immediate dilution if the company sells common stock or preferred stock in the future.

Future Outlook

The company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up. The company may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although there are no current commitments or agreements.

Industry Context

This offering is typical for clinical-stage biopharmaceutical companies seeking to raise capital to fund ongoing research and development activities. The use of a 'best efforts' offering and warrants is a common strategy to attract investors in a volatile market.

Comparison to Industry Standards

• Comparable companies like Actinium Pharmaceuticals, Inc. and Diffusion Pharmaceuticals Inc. have recently conducted similar public offerings to fund clinical trials and general corporate purposes.
• The terms of this offering, including the use of warrants and a placement agent, are consistent with industry standards for small-cap biotech companies.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The company's employees may benefit from increased funding for research and development.
• The company's customers (patients) may benefit from the development of new therapies.
• The company's suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• The company will work with the placement agent to solicit offers to purchase the securities.
• The company will determine the final offering price and enter into securities purchase agreements with investors.
• The offering is expected to close on or about , 2024.
• The company will use the net proceeds for working capital and general corporate purposes.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Theriva Biologics, capital raise, best efforts, placement agent, NYSE American, TOVX